INSM.O (INSM.O) News
Track canonical SquawkNews coverage tagged to INSM.O, INSM.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Insmed shares up on FDA priority review for lung disease drug
Insmed Inc shares rose 2% premarket to $122.41 after the U.S. Food and Drug Administration granted priority review for its Arikayce drug to treat Mycobacterium avium complex lung disease. Full approval could expand its u
EQUITY | Sep 21, 2026, 12:43 PM UTC
M
FDA grants priority review to Insmed's ARIKAYCE for MAC lung disease
FDA accepted Insmed's supplemental New Drug Application (sNDA) for ARIKAYCE in MAC lung disease as part of combination therapy, granting Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is s
REGULATION | Sep 21, 2026, 11:08 AM UTC